ስለ Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
ዋና መሥሪያ ቤት251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
የተመሠረተ2018
ሁኔታንቁ
ፓተንቶች1 ፓተንት
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
የሕግ መረጃ
| ሕጋዊ ስም | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20በGLEIF ላይ ይመልከቱ ↗ |
| የተመዘገበ አድራሻ | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| ሁኔታ | ንቁ |
ምንጮች: GLEIF · የተዘመነ Oct. 16, 2026
እውቂያ & አገናኞች
ቦታ
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
ይህ ኩባንያዎ ነው?
አርማዎን፣ ምርቶችዎን፣ ፎቶዎችዎን እና ሥራዎችዎን ለመጨመር እና ግምገማዎችን ለመመለስ ይህን ገጽ በነፃ ይውሰዱ።
ይህን ገጽ ይውሰዱለመገናኘት፣ ለመቅጠር እና ለማደግ Heelkyን ይቀላቀሉ
ለሰዎች መልዕክት ለመላክ፣ ለሥራ ለማመልከት እና ተልዕኮዎችን ለመለጠፍ ነፃ መለያ ይፍጠሩ።
አሁን ይቀላቀሉ — ነፃ ነው